Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line
- Department of Oncology, Radiology and Clinical Immunology, Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala (Sweden)
- Affibody AB, P.O. Box 20137, SE-161 02 Bromma (Sweden)
- Ludwig Institute for Cancer Research, Uppsala University, Uppsala (Sweden)
HER2-specific affibody molecules in different formats have previously been shown to be useful tumor targeting agents for radionuclide-based imaging and therapy applications, but their biological effect on tumor cells is not well known. In this study, two dimeric ((Z{sub HER2:4}){sub 2} and (Z{sub HER2:342}){sub 2}) and one monomeric (Z{sub HER2:342}) HER2-specific affibody molecules are investigated with respect to biological activity. Both (Z{sub HER2:4}){sub 2} and (Z{sub HER2:342}){sub 2} were found to decrease the growth rate of SKBR-3 cells to the same extent as the antibody trastuzumab. When the substances were removed, the cells treated with the dimeric affibody molecules continued to be growth suppressed while the cells treated with trastuzumab immediately resumed normal proliferation. The effects of Z{sub HER2:342} were minor on both proliferation and cell signaling. The dimeric (Z{sub HER2:4}){sub 2} and (Z{sub HER2:342}){sub 2} both reduced growth of SKBR-3 cells and may prove therapeutically useful either by themselves or as carriers of radionuclides or other cytotoxic agents.
- OSTI ID:
- 21255780
- Journal Information:
- Biochemical and Biophysical Research Communications, Vol. 377, Issue 2; Other Information: DOI: 10.1016/j.bbrc.2008.10.027; PII: S0006-291X(08)01963-3; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
- Country of Publication:
- United States
- Language:
- English
Similar Records
SU-E-I-81: Targeting of HER2-Expressing Tumors with Dual PET-MR Imaging Probes
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin